Pharma Monopoly spotted at @rizzolibooks.bsky.social in NYC. If you’re in New York, I’ll be in conversation with A. Kayum Ahmed on Thursday, June 11 at 6PM at The People's Forum for the U.S launch of Pharma Monopoly. RSVP here: docs.google.com/forms/d/e/1F...

SCOTUS's 9-0 ruling in Hikma v. Amarin prevented an attempt to dilute how skinny labelling as conceived was intended to work, but that this case even got this far shows where we are... www.supremecourt.gov/opinions/25p...

Thank you Sonali Kolhatkar for having me on the show to talk about drug pricing and my new co-authored book, Pharma Monopoly. risingupwithsonali.com/heres-how-we...

What makes this more striking is that it doesn't even include Zepbound (Eli Lilly's higher-dose tirzepatide product), which now makes as much revenue as Mounjaro in the U.S.

It was a pleasure to speak with Aisha Nyandoro for @forbes.com on the occasion of the U.S release of Pharma Monopoly. www.forbes.com/sites/aishan...

Join us for two upcoming events on occasion of @tahiramin.bsky.social's new co-authored book, Pharma Monopoly! Details below.

In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,” we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain. www.statnews.com/2026/05/26/h...

@tahiramin.bsky.social and Rohit Malpani. The innovation trap: How pharma weaponizes a word to extend monopolies www.statnews.com/2026/05/26/h... via @statnews.com

Pharma Monopoly: The Battle for the Future of Medicines, co-authored with Rohit Malpani, is now on sale in the U.S.

Happy publication day, Tahir!  Billions are denied affordable medicine by outdated patent rules and neoliberal policies. In PHARMA MONOPOLY, @tahiramin.bsky.social and Rohit Malpani expose how governments ceded control to pharmaceutical giants—and how we can undo the damage.

“The business model of using patents and the language of innovation to justify prolonged patent monopolies that keep knowledge privatized for longer than necessary is endemic across the pharmaceutical industry” @tahiramin.bsky.social @statnews.com www.statnews.com/2026/05/26/h...

Read an excellent excerpt from @tahiramin.bsky.social’s new book: PHARMA MONOPOLY in @truthdig.com 👇👇👇

A new book explains why drugs cost so much in the United States — and why Trump’s claims about addressing the crisis are bogus. www.truthdig.com/articles/at-...

@truthdig.com ran an excerpt from a chapter in my co-authored book, Pharma Monopoly, that traces how the drug industry and U.S foreign policymakers became partners in expanding the industry’s monopoly power. www.truthdig.com/articles/at-...

My latest op-ed in @marketwatch.com. 40% of the world will soon have access to Ozempic and Wegovy generics. But not Americans. And we have our Reagan-era drug laws to thank for that. www.marketwatch.com/story/canada...

This slide is from Definium's recent investor call. It shows how they intend to build a monopoly around a derivative of LSD they've dubbed DT120 ODT despite the active ingredient, LSD, being nearly 90 years old.🧵

I'll be in conversation with A. Kayum Ahmed on June 11 at The People's Forum in NYC to discuss my newly co-authored book, Pharma Monopoly. Please join us. RSVP below. docs.google.com/forms/d/e/1F...

“A relatively small share of Americans stand to directly benefit from these moves...But for many Americans struggling with a range of surging costs, the president’s drug pricing moves have not translated into direct savings." www.nytimes.com/2026/05/18/b...

Good to see a current Senate candidate and 2028 hopeful focus on drug pricing and pharma lobbying. If @ossoff.bsky.social wants to get specific about policies that are both popular and get to the root of the drug pricing problem, he should join the bipartisan momentum for patent reform.

The ruse of neoliberalism’s “rules-based order” is more exposed than it’s ever been. In Hindu Business Line, I pull on themes from my upcoming book to explain how countries like India can use this moment to build systems that truly serve the public good. www.thehindubusinessline.com/specials/pul...

Good that both parties are connecting affordability to root causes. And good that pharma is losing some "friends". If we really want to see lower drug prices, we’ll need to see more “unfriending” of the pharmaceutical lobby, especially within the PTO and FDA.

Coming out this month! Pharma Monopoly: The Battle for the Future of Medicines @tahiramin.bsky.social & Rohit Malpani (two respected scholars of access to meds) www.politybooks.com/bookdetail?b...

Why is the price of the cancer drug Revlimid increasing even though lower-cost generics are on the market? Because Celgene/BMS used a new kind of “pay-for-delay” deal that is harder for regulators to catch: a “limited-volume settlement.”

Thank you @tahiramin.bsky.social @imakglobal.bsky.social for supporting @fr.publiceye.ch in our patent analysis of cancer drug #Keytruda, in conjunction with @icij.org, unveiling MSD's gaming of the patent systems to maintain overinflated prices & delay competition www.publiceye.ch/en/topics/ph...

Our team at @imakglobal.bsky.social provided patenting data to @icij.org for their investigation into Merck's Keytruda. The ICIJ reviewed the data and built a visualization of Merck’s patent portfolio.

A team of journalists at the @icij.org and 47 media partners in 37 countries just published a yearlong investigation into how Merck built its global Keytruda monopoly.

Our team at @imakglobal.bsky.social released a new brief, The Monopoly Extension Menu.🧵 reports.i-mak.org/monopoly-ext...

Really looking forward to chatting to my old friend @tahiramin.bsky.social about his new book Pharma Monopoly. 27.04 in London 👇 www.eventbrite.co.uk/e/tahir-amin...

GLP-1 sales accounted for about 74% of Novo’s total revenue last year. Novo will generate an est. $94B from U.S. GLP-1 sales between 2018-2026. They’re expected to return up to $68B, or 72 cents of every dollar, to shareholders via buybacks and dividends, during that same period.

Important reporting by The New York Times. The primary patents on Novo Nordisk’s Ozempic and Wegovy should expire today. Generics are expected to launch in India shortly after, followed by China, Canada, Brazil, Turkey, and South Africa. 1/ www.nytimes.com/2026/03/19/h...

In his SOTU, President Trump claimed he is “ending the wildly inflated costs of prescription drugs." "Other presidents tried to do it but they never could,” he said. “I got it done.” TrumpRX is a gimmick. 🧵

Tech and pharma will pour money into AI-related lobbying this year, especially to shape IP policy. Tech will push for carve outs while pharma will demand we expand what counts as patentable to include AI-assisted discoveries so they can generate more follow-on patents.

Sen Coons: "I was in-house counsel to a global company that had a very large patent estate.” Fox in the henhouse comes to mind.

Good point by Tim Wu. The pharma market is especially prone to extraction because pharma patents/IP confer power that patents/IP in other fields of technology simply don’t.

Excellent substack from Thomas Krause. A linear, logical explanation of a simple truth: creating patent thickets is standard practice and patients pay the price. substack.com/home/post/p-...

Very excited to be partnering with @tahiramin.bsky.social, @miracleworkerpr.bsky.social, @lauradigiovine.bsky.social and @politybooks.bsky.social books to usher PHARMA MONOPOLY into the world. Media friends, let me know if we can send you a galley.

Medicare's Drug Price Negotiation Program recently announced the 15 drugs selected for its third round of negotiations. As the program expands, its success is in danger of being undercut by legislators giving drug companies new ways to extend their monopolies. 🧵 www.statnews.com/2026/01/27/m...

“Drug companies, including the 16 that made deals [with the Trump administration], raised the prices of 872 brand-name drugs in the first two weeks of 2026” www.npr.org/2026/01/16/n...

Price hikes by pharma companies between Jan 1 and Jan 9

I’m excited to share that my first book, Pharma Monopoly: The Battle for the Future of Medicines, co-written with Rohit Malpani, will be published in March in the UK/Europe and May in the U.S.

This is called product hopping.

“Moving patients to the newer version is key for Bristol because it has a longer patent life than the mainstay version of the drug that’s infused…Bristol also hopes the newer version can avoid being part of price negotiations under the Inflation Reduction Act…”

We will continue to fight for that world that David dreamed of, a world where lifesaving medicines can be within reach of every patient. Rest in power, David.

He should launch a generic drug company and take on big pharma patent monopolies next.

Get ready for pharma companies to ratchet up “lifecycle management” strategies under the language of “innovation” to squeeze even more $ from their blockbusters as they all chase the new $1T benchmark

👏 NEWS: Teva removes over 200 improper Orange Book patent listings under pressure from the FTC. 🔗 www.fiercepharma.com/pharma/ftc-c...

Good to see the FTC continue Lina Khan's policies of enforcement against improper patent listings

Our team at @imakglobal.bsky.social partnered with @statnews.com to analyze our @fandmpoll.bsky.social survey on how the public views drug pricing. What stands out is how Americans across the political spectrum support patent reform.

This is true. Look at AbbVie’s CEO. It says a lot about a pharma company's priorities when their CEO's bio focuses entirely on financial achievements.

The TRIPS Agreement has nothing to do with free trade and everything to do with protecting corporate monopolies. It’s why pharma was able to block South Africa from purchasing HIV/AIDS treatments in the '90s and why Moderna and J&J were able to monopolize COVID vaccines.